Treatment of relapsed multiple myeloma: Evidence-based recommendations

The practice of choosing the next best therapy for patients with relapsed and/or refractory multiple myeloma (RRMM) is becoming increasingly complex. There is no clear consensus regarding the best treatment sequence for RRMM. With the approval of novel proteasome inhibitors (ixazomib and carfilzomib...

Full description

Saved in:
Bibliographic Details
Published in:Blood reviews 2020-01, Vol.39, p.100616-100616, Article 100616
Main Authors: Durer, Ceren, Durer, Seren, Lee, Sarah, Chakraborty, Rajshekhar, Malik, Mustafa Nadeem, Rafae, Abdul, Zar, Muhammad Abu, Kamal, Ahmad, Rosko, Nathaniel, Samaras, Christy, Valent, Jason, Chaulagain, Chakra, Anwer, Faiz
Format: Article
Language:English
Subjects:
Evidence-based
Multiple myeloma
Refractory
Relapsed
Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The practice of choosing the next best therapy for patients with relapsed and/or refractory multiple myeloma (RRMM) is becoming increasingly complex. There is no clear consensus regarding the best treatment sequence for RRMM. With the approval of novel proteasome inhibitors (ixazomib and carfilzomib), immunomodulatory agents (pomalidomide), monoclonal antibodies (daratumumab and elotuzumab), and other targeted therapies, multiple combination regimens utilizing these agents are being studied with the goal of enhancing disease control, prolonging progression-free survival, and improving overall survival. We, herein, describe a review of FDA-approved regimens for RRMM patients and offer a paradigm in selecting subsequent treatment regimens, focusing on patient specific morbidity, treatment toxicity, and disease-specific characteristics.
ISSN:0268-960X
1532-1681
DOI:10.1016/j.blre.2019.100616